Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Recombinant, nonreplicating, human adenovirus serotype 5-vectored vaccine, known as MRKAd5, expressing three HIV-1 clade B-derived internal proteins when used in a homologous immunization regimen, did not decrease HIV-1 infection rate nor postinfection virus load in the first Phase IIb proof-of-concept trial. However, the vaccine did not reach the limits of vaccine T-cell induction and its design can be improved both from the point of the HIV-1-derived immunogens and their delivery. Therefore, failure of the first experimental HIV-1 vaccine focusing on induction of T-cell responses cannot be a reason for dismissal of the whole T-cell vaccine concept, nor for losing a positive attitude toward systematic HIV-1 vaccine development.

Original publication

DOI

10.1586/14760584.7.3.303

Type

Journal article

Journal

Expert Rev Vaccines

Publication Date

04/2008

Volume

7

Pages

303 - 309

Keywords

AIDS Vaccines, Clinical Trials, Phase II as Topic, HIV Infections, HIV-1, Humans, T-Lymphocytes, Treatment Failure, Viral Load